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Renal transplant recipients are at increased risk of bladder carcinoma. The aetiology is unknown but a polyoma virus (PV), BK virus
(BKV), may play a role; urinary reactivation of this virus is common post-renal transplantation and PV large T-antigen (T-Ag) has
transforming activity. In this study, we investigate the potential role of BKV in post-transplant urothelial carcinoma by immunostaining
tumour tissue for PV T-Ag. There was no positivity for PV T-Ag in urothelial carcinomas from 20 non-transplant patients. Since 1990,
10 transplant recipients in our unit have developed urothelial carcinoma, and tumour tissue was available in eight recipients. Two
patients were transplanted since the first case of PV nephropathy (PVN) was diagnosed in our unit in 2000 and both showed PV
reactivation post-transplantation. In one of these patients, there was strong nuclear staining for PV T-Ag in tumour cells, with no
staining of non-neoplastic urothelium. We conclude that PV infection is not associated with urothelial carcinoma in non-transplant
patients, and is uncommon in transplant-associated tumours. Its presence in all tumour cells in one patient transplanted in the PVN
era might suggest a possible role in tumorigenesis in that case.
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Renal transplant recipients carry a three- to four-fold increased
risk of urothelial carcinoma when compared with the general
population, the cause of which is unknown (Birkeland et al, 1995;
Buzzeo et al, 1997; Vajdic et al, 2006). Infection with oncogenic
viruses is one possible explanation, and BK virus (BKV) is a
potential candidate virus.
BKV, a polyoma virus (PV), was first identified in 1971, in a
renal transplant recipient with ureteric stenosis (Gardner et al,
1971). It infects 90% of the population during childhood and
subsequently remains latent in the epithelium of the urinary tract.
Urinary reactivation of the virus is seen in approximately 30% of
renal transplant recipients receiving modern immunosuppressive
protocols (Thamboo et al, 2007). Persistent high levels of urothelial
reactivation are associated with an increased risk of infection of
the renal tubules within the graft, resulting in PV nephropathy
(PVN) that occurs in 3–5% of renal transplant recipients. This is a
relatively recent phenomenon that was first described in 1995
(Purighalla et al, 1995). The first patient with PVN in our unit in
Oxford was diagnosed in 2000 (Thamboo et al, 2007). Current
potent immunosuppressive regimens, the combination of tacroli-
mus and mycophenolate mofetil (MMF) in particular, have been
implicated in the emergence of this complication.
The polyoma viruses, including BKV, have transforming
activity, although a role in human neoplasia is yet to be
demonstrated. PV expresses a viral oncogene, the large T-antigen
(T-Ag) that inactivates the pocket protein family, including pRb. It
has recently been demonstrated that the BKV T-Ag activates the
DNA methyltransferase 1 gene – DNMT1 (McCabe et al, 2006).
DNMT1 is associated with tumorigenesis through tumour
suppressor gene hypermethylation.
In this study, we investigate the potential role of BKV in
urothelial carcinoma in immunocompetent individuals and
following renal transplantation by staining of tumour tissue with
antibody against PV T-Ag.
MATERIALS AND METHODS
Patients
Search of the local renal transplant database (1990–2007) revealed
10 patients with post-transplant urothelial carcinoma of the
bladder in our unit, eight of whom had archival paraffin blocks
of tumour tissue available for study. A control group of
immunocompetent individuals with carcinoma of the bladder
was identified. These were 20 consecutive non-transplant patients
diagnosed with high-grade invasive urothelial carcinoma in 2006.
Ethics approval was obtained for the study of bladder tumours
and renal tissue from renal transplant recipients (ethics committee
reference numbers O-02.062 and 04/Q1606/96).
Immunohistochemistry (IH)
Immunohistochemistry for PV T-Ag was performed using a
primary monoclonal anti-SV40 T-Ag (Calbiochem, San Diego,
CA, USA). This antibody stains all human polyoma viruses,
including BKV. Before incubation with the antibody, antigen
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sretrieval was performed using a pressure cooker for 60–90s at high
pressure, with paraffin sections in 0.01 M citrate buffer at pH 6. Primary
antibody staining was done for 30min at a dilution of 1/200. The
detection system used was Vector Elite ABC, Burlingame, CA, USA.
RESULTS
The 20 non-transplant tumours were all negative for PV T-Ag on IH.
The patients with transplant-associated urothelial carcinoma are
summarised in Table 1. Of the eight patients with tissue available
for review and staining, the mean age at diagnosis was 58 years
and male/female ratio was 2:6. Two patients (7 and 8) were
transplanted since the first case of BKV nephropathy was
diagnosed in Oxford in 2000. Both patients showed post-transplant
reactivation of BKV, one diagnosed on renal biopsy and the other
on urine cytology.
One of eight urothelial carcinomas in transplant recipients
(patient 7) showed strong nuclear staining for PV T-Ag in virtually
all tumour cells, with negative staining in adjacent non-neoplastic
urothelium (Figure 1). Typical intranuclear inclusions were not
seen on H&E sections and there was no lymphocytic response to
Table 1 Patients with post-renal transplant urothelial carcinoma (UC) of the bladder
Patient
number
Sex/age at
diagnosis
Transplant
year
Time from transplant to UC diagnosis
(months)
Grade/stage of UC at
diagnosis
PV T-Ag
staining
1 F/75 years 1990 129 Low grade/Ta Negative
2 M/53 years 1990 38 High grade/T1 Negative
3 F/69 years 1992 121 High grade/T2 Negative
4 F/41 years 1993 147 High grade/T2 Negative
5 F/56 years 1995 68 High grade/T2 Negative
6 M/61 years 1996 129 High grade/T3 Negative
7 F/40 years 2001 54 High grade/T3 Positive
8 F/65 years 2004 33 High grade/Tis Negative
AB
CD
EF
Figure 1 Tumour tissue from patient 7, showing high-grade invasive urothelial carcinoma (A), with focal squamous differentiation (B). High power
(C) reveals no evidence of typical viral inclusions on H&E stain. Immunohistochemistry for PV T-Ag is negative in non-neoplastic urothelium adjacent to the
tumour (D), but shows intense nuclear staining in almost all tumour cells (E and F).
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sthe PV-positive tumour cells, even following reduced immuno-
suppression for 6 weeks after diagnosis and before cystectomy.
Patient 7 is a 40-year-old woman, who received a renal
transplant in 2001. Her initial immunosuppression was ciclosporin,
azathioprine and prednisolone. However, she suffered three
early rejections: a Banff 97 type IA rejection at day 7 post-
transplantation, treated with 3 days of pulse methylprednisolone;
a Banff 97 type III rejection at 13 days post-transplantation, treated
with antithymocyte globulin and a Banff 97 type IB rejection,
diagnosed at 27 days post-transplantation. The latter was treated
with a second 3-day course of pulse methylprednisolone, followed
by switch of ciclosporin and azathioprine to tacrolimus and MMF.
No urine cytology to detect PV reactivation was performed, but
PVN was diagnosed retrospectively using IH for PV T-Ag in a renal
biopsy performed for graft dysfunction at 2 years post-transplan-
tation (Figure 2). This showed a minor non-specific infiltrate with
no viral inclusions apparent on the H&E stain. Her bladder tumour
was diagnosed 4 years post-transplantation and was treated with
radical cystectomy, bilateral native nephrectomy and hysterec-
tomy. Her renal allograft shows good functioning 6 years post-
transplantation (serum creatinine 137mmoll
1).
Patient 8 is a 65-year-old woman, transplanted in 2004. She
developed BKV reactivation 5 months post-transplantation,
diagnosed on urine cytology, but did not have biopsy-proven
BKV nephropathy. She developed graft dysfunction 2.5 years post-
transplantation, biopsy showing chronic damage with active
AB
Figure 2 Renal biopsy 2 years post-transplantation from patient 7, showing a minor non-specific inflammatory cell infiltrate on H&E
(A). Immunohistochemistry for PV T-Ag (B) shows staining of tubular epithelial cell nuclei, confirming a diagnosis of PVN.
AB
C
Figure 3 Urine cytology in patient 8 initially suggested BKV infection (A) but a sample 3 months later was more in keeping with urothelial carcinoma (B),
confirmed as carcinoma in situ on biopsy (C).
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atypical cells distributed singly, which were initially interpreted as
decoy cells, indicative of BKV infection (Figure 3A). However, in
the third urine specimen (3 months after the first), aggregates of
atypical cells were present, suggesting high-grade urothelial
carcinoma (Figure 3B). Urothelial carcinoma in situ was confirmed
on biopsy (Figure 3C) and this was negative for PV T-Ag.
DISCUSSION
There is conflicting evidence of a role for BKV in urothelial
carcinoma in immunocompetent individuals. Weinreb et al (2006)
reported a significant association between urine cytology sugges-
tive of PV infection and subsequent diagnosis of bladder
carcinoma. However, this study did not confirm PV positivity
with IH and the urinary findings may have been secondary to early
urothelial carcinoma. The distinction of BKV infection from
urothelial malignancy can be very difficult on cytomorphology
alone, as illustrated by a recent study (Glatz et al, 2006) and by
case 8 in our series. In a case–control study, Newton et al (2005)
found no association between prevalence or titres of anti-BKV
antibodies and diagnosis of bladder cancer. A recent tissue-based
study detected BKV DNA by PCR in only 5.5% of urothelial
carcinomas, all of which were negative on IH for BKV T-Ag
(Rollison et al, 2007). Similarly, we found no evidence of PV T-Ag
in urothelial carcinoma from 20 immunocompetent patients.
There has been no previous systematic study of BKV in
transplant-associated urothelial carcinoma. Geetha et al (2002)
reported a single patient who developed PVN following
simultaneous pancreas–kidney transplant and who subsequently
developed carcinoma of the bladder that was diffusely positive for
PV T-Ag on IH, confirmed to be BKV by PCR. Patient 7 in our series
closely resembles this case. PV T-Ag positivity in the tumour tissue
of our patient implicates a polyoma virus in tumorigenesis but is not
specific for BKV. Although this is the most likely candidate virus,
BKV-specific PCR was not performed and the presence of another
polyoma virus could not be excluded. The association of PV-
positive urothelial carcinoma and PVN in these patients suggests
that persistent or high levels of post-transplant urinary reactivation
of BKV may have a pathogenic role in the development of urothelial
carcinoma. Alternatively, it is possible that tumour cells are more
susceptible to BKV infection than normal urothelium, as infection
occurs primarily in proliferating cells, and that positivity is a
consequence rather than cause of neoplastic transformation. Urine
cytology screening for BKV reactivation post-transplantation is now
routine in many units, including ours. Long-term follow-up of these
patients is required to demonstrate an association between viral
reactivation and subsequent tumour development, and thus confirm
the potential oncogenic role of BKV.
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